Published in Clin Exp Immunol on October 01, 2004
Failure of TLR4-driven NF-kappa B activation to stimulate virus replication in models of HIV type 1 activation. AIDS Res Hum Retroviruses (2007) 0.94
HIV type 1 infection up-regulates TLR2 and TLR4 expression and function in vivo and in vitro. AIDS Res Hum Retroviruses (2012) 0.89
Insights into Soluble Toll-Like Receptor 2 as a Downregulator of Virally Induced Inflammation. Front Immunol (2016) 0.87
Constitutive gene expression in monocytes from chronic HIV-1 infection overlaps with acute Toll-like receptor induced monocyte activation profiles. PLoS One (2012) 0.86
Mechanism(s) involved in opioid drug abuse modulation of HAND. Curr HIV Res (2012) 0.83
A role for TLR signaling during B cell activation in antiretroviral-treated HIV individuals. AIDS Res Hum Retroviruses (2013) 0.80
Chronic morphine and HIV-1 Tat promote differential central nervous system trafficking of CD3+ and Ly6C+ immune cells in a murine Streptococcus pneumoniae infection model. J Neuroinflammation (2015) 0.77
Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy. Front Immunol (2016) 0.75
Toll-like receptor-2 exacerbates murine acute viral hepatitis. Immunology (2016) 0.75
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation (2001) 3.86
HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med (1999) 3.01
RANTES: a versatile and controversial chemokine. Trends Immunol (2001) 2.87
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (2001) 2.87
HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med (2003) 2.62
Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol (2000) 2.49
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol (1996) 1.70
Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev (2000) 1.54
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res (2000) 1.53
Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J (1998) 1.35
Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques (2002) 1.33
Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. J Leukoc Biol (2000) 1.14
Increased expression of toll-like receptor 2 on monocytes in HIV infection: possible roles in inflammation and viral replication. Clin Infect Dis (2004) 1.11
Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood (2003) 1.11
RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis (2001) 1.07
Chemokines as natural HIV antagonists. Curr Mol Med (2002) 1.05
C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol (1997) 1.05
Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2. J Immunol (2003) 1.04
Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS (1999) 1.02
Chemokines and viruses: the dearest enemies. Virology (2000) 1.00
RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am J Physiol (1997) 0.99
Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis (1998) 0.94
Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection. J Leukoc Biol (2003) 0.89
Chemokine induction by HIV-1: recruitment to the cause. Trends Immunol (2003) 0.88
RANTES and MIP-1beta mRNA expression in human peripheral blood mononuclear cells: transcript quantification using NASBA technology. J Immunol Methods (2001) 0.78
A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods (1986) 8.88
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med (1989) 6.99
Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol (1999) 6.60
Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem (1999) 5.81
Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol (1999) 4.77
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med (1992) 4.02
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med (1994) 3.73
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med (1988) 2.92
Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med (1989) 2.68
Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol (2000) 2.49
The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol (1999) 2.44
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet (1995) 2.43
Cutting edge: cells that carry A null allele for toll-like receptor 2 are capable of responding to endotoxin. J Immunol (1999) 2.22
High-intensity interval training improves peak oxygen uptake and muscular exercise capacity in heart transplant recipients. Am J Transplant (2012) 2.08
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med (2001) 1.95
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis (1994) 1.93
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol (1999) 1.86
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med (1988) 1.82
Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol (1989) 1.76
Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun (2001) 1.75
A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol (1992) 1.75
CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. Cardiovasc Res (2000) 1.74
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol (2001) 1.71
Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia (2006) 1.63
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol (2001) 1.58
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest (2001) 1.55
IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol (1999) 1.55
Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost (2006) 1.55
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res (2000) 1.53
Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med (2009) 1.53
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation (1999) 1.53
Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J (2001) 1.51
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Primary immunodeficiency diseases in Norway. J Clin Immunol (2000) 1.48
Elevated plasma levels of reduced homocysteine in common variable immunodeficiency--a marker of enhanced oxidative stress. Eur J Clin Invest (1997) 1.48
Cytokine regulation of interleukin 6 production by human endothelial cells. Cell Immunol (1989) 1.46
Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation (1998) 1.46
Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial. Am J Transplant (2012) 1.45
Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect Dis Clin North Am (1999) 1.43
[Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin]. Tidsskr Nor Laegeforen (2001) 1.40
[Natural products can be hazardous to health]. Tidsskr Nor Laegeforen (1992) 1.39
[The chemical working environment among car painters in Bergen]. Tidsskr Nor Laegeforen (1994) 1.39
Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med (1990) 1.39
Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. Heart (2005) 1.38
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol (2009) 1.37
Activation of human monocytic cells by Borrelia burgdorferi and Treponema pallidum is facilitated by CD14 and correlates with surface exposure of spirochetal lipoproteins. J Immunol (1999) 1.36
Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J (1998) 1.35
Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol (1989) 1.35
Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol (1998) 1.34
Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis (1994) 1.33
Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol (2000) 1.32
Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol (2001) 1.31
Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation (2001) 1.29
Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab (1998) 1.29
Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol (1986) 1.29
Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant (2001) 1.26
Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J Exp Med (1989) 1.26